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Abstract: Mitochondrial diseases are a heterogeneous group of disorders that are currently the focus of intense research. The many cell
functions performed by mitochondria include ATP production, calcium homeostasis, and apoptosis. One of the unique properties of
mitochondria is the existence of a separate mitochondrial genome (mitochondrial DNA, mtDNA) found in varying copy numbers and
containing 37 genes, 13 of them encoding proteins. All 13 mitochondrially encoded proteins form part of oxidative phosphorylation
complexes through combination with approximately 100 nuclear DNA-encoded proteins. Coregulation of nDNA and mtDNA is
therefore essential for mitochondrial function, and this coregulation contributes to the heterogeneity and complexity observed in
mitochondrial disorders. In recent times, significant advances have been made in our understanding of mtDNA-related disorders. A
comprehensive review of these studies will benefit both current and new researchers and clinicians involved in the field. This review
examines the major types of mtDNA-related defects and their pathogenic mechanisms, with a special emphasis on the heterogeneity of
mitochondrial disorders. Potential treatment strategies specialized for each of the disorders, including the hormone melatonin and the
recent advances in gene therapy, related to their potential applications for the management of the primary mtDNA disorders are also
discussed.
Key words: Mitochondria, oxidative phosphorylation, mitochondrial DNA, mitochondrial DNA disorders, mitochondrial DNA
mutations

1. Introduction
Mitochondria are the organelles with the main
responsibility for energy production in cells, generated
in the form of ATP by oxidative phosphorylation
(OXPHOS). Mitochondria are additionally involved in
many other important processes, including apoptosis
and calcium homeostasis (Pozzan et al., 2000; Newmeyer
and Ferguson-Miller, 2003). Furthermore, mitochondria
are the main site of the production of reactive oxygen
species (ROS). The tricarboxylic acid (TCA) cycle, which
in addition to its contribution to ATP production also
generates several important metabolic intermediates,
occurs in mitochondria (Boveris et al., 1972).
Mitochondria contain their own genetic material, called
mitochondrial DNA (mtDNA), a 16,569-bp-long, doublestranded, circular molecule containing just 37 genes. Only
13 of these genes encode proteins, all of them contributing
to the formation of OXPHOS complexes through
association with nuclear DNA (nDNA)-encoded proteins.
The remaining genes encode 22 tRNAs and 2 rRNAs
(Anderson et al., 1981). The copy number of mtDNA varies
depending on the cell type and energy demand of the tissue.
* Correspondence: ucagin@cnic.es
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Replication of mtDNA is dependent on proteins encoded by
nDNA and imported to mitochondria. Therefore, mtDNArelated diseases can be caused not only by mutations in
mtDNA but also by defects in nDNA-encoded factors
required for mtDNA replication (Figure 1). This dualdependence of mtDNA integrity is largely responsible for
the heterogeneous nature of mtDNA-related diseases.
The history of research on mtDNA-related diseases
is relatively short, with the first disease-causing mtDNA
mutations reported in 1988 (Holt et al., 1988; Wallace et al.,
1988). These two ground-breaking studies paved the way
to the discovery and characterization of a large number of
mtDNA mutations, and at least 300 pathogenic mtDNA
mutations have now been identified (www.mitomap.org).
Due to the high degree of heterogeneity in mtDNA-related
diseases, it is very hard to quantify their prevalence. Studies
have been conducted to define the severity of mtDNA
mutations in specific populations; however, a worldwide
study in this field is missing. A study based in northeastern
England reported that mtDNA-related diseases occurred
at a frequency of 1 in 10,000 in working-age adults with
a further 1 in 6000 people (below retirement age) at
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risk of developing these diseases (Schaefer et al., 2008).
Subsequent reports have suggested that the frequency of
mtDNA mutations is much higher (Greaves et al., 2012).
Recent advances in molecular biology and sequencing
techniques will inevitably lead to the characterization of
new mtDNA mutations, which will help provide a more
accurate estimate of the prevalence of these diseases, and
thereby a better understanding of the impact of mtDNArelated diseases on society.
The mechanisms underlying mtDNA-related disorders
can explain why they are associated with such a high
degree of clinical heterogeneity. The mechanistic details of
mtDNA dysfunction need to be investigated in depth in
order to design novel therapeutic strategies. This review
examines the state of the art regarding these mechanisms
and reviews some recent therapeutic advances in the field.
2. Features of mtDNA genetics
2.1. The mtDNA molecule at a glance
The publication of the first sequence of human mtDNA
in 1981 marked a milestone in mitochondrial research
(Anderson et al., 1981). Our current understanding of
the mtDNA sequence incorporates subsequent revisions
(Andrews et al., 1999). The mtDNA molecule contains
no introns and only a few noncoding bases (Anderson
et al., 1981). The molecule is formed by a guanine-rich
heavy strand (H) and a cytosine-rich light strand (L). The
only noncoding region in mtDNA is called the D-loop
(displacement loop) and it contains control elements
required for mtDNA transcription and replication (Shadel
and Clayton, 1997). Unlike the nuclear genome, which is
found in 2 copies of 23 chromosomes (2n = 46), mtDNA
can occur in multiple copy numbers. The maintenance of
mtDNA copy number is discussed in a separate section.
mtDNA exists in protein-linked structures called
nucleoids, compact macrocomplexes formed and
stabilized principally through the action of mitochondrial
transcription factor A (TFAM) (Kaufman et al., 2007).
mtDNA nucleoid-associated proteins are a subject of
intense research but as of yet there is no consensus on their
characteristics or number (Hensen et al., 2014). Further
advances in this area will provide a clearer picture on the
role of nucleoid structure in mtDNA maintenance.
Maintenance and homeostasis of mtDNA is determined
by various processes specialized for their function. In the
following sections we review some of the key features of
mtDNA in order to provide a better understanding of
mtDNA-related diseases and their mechanisms. These
features should be taken into account during diagnosis
and treatment of mitochondrial disease patients.
2.2. Heteroplasmy and threshold
MtDNA accumulates mutations at a fast rate, leading to
mitochondrial dysfunction. The inherent ROS formation

associated with the OXPHOS system might be the primary
cause of the accumulation of mutations in mtDNA (Brown
et al., 1979). Nonmutated and mutated mtDNA copies can
coexist in the same cell and even in the same mitochondria,
a condition called heteroplasmy. MtDNA mutations can
also be found in a homoplasmic state, when no nonmutated
mtDNA copies are present. In the heteroplasmic state,
the proportion of mutated mtDNA copies needs to
pass a certain threshold in order to cause a pathological
defect detectable by biochemical tests. However, there
is no clear correlation between the heteroplasmy level
and the clinical severity of disease (Wong, 2007), and
the threshold level can vary depending on the mutation
type, adding another level of complexity to the treatment
of mtDNA-related disorders. A recent study showed that
small changes in mtDNA heteroplasmy cause significant
changes in the nDNA transcriptome (Picard et al., 2014).
This transcriptional reprogramming upon mitochondrial
dysfunction is also known as retrograde signaling and is
activated by changes in ATP/AMP, NADH/NAD+, ROS,
cytosolic Ca2+, and membrane potential. These changes
are interpreted by the cells as signals of mitochondrial
dysfunction. Retrograde signaling further causes changes
in expression of genes involved in various signaling
pathways (e.g., mTOR, Myc, NFKB), mitochondrial
transcription, capacity, or biogenesis and usually causes a
metabolic switch towards glycolysis. The interconnected
complex mechanism of this phenomenon is the subject of
a recent review by our group (Cagin and Enriquez, 2015).
2.3. Random segregation, mtDNA bottleneck, and clonal
expansion
Mitochondrial segregation during cell division has been
suggested to be random, which need to be investigated
in deeper detail (Lombes et al., 2014). This suggests that
the segregation of mitochondria carrying mutant and
wild-type mtDNA will result in one daughter cell having
more mutant mtDNA and the other having more wildtype mtDNA. Random mitochondrial segregation would
result in the production of daughter cells with varying
proportions of putatively mutant mtDNA. If the mutant
mtDNA proportion exceeds a certain threshold level, a
biochemical defect will be evident. In contrast, in fastdividing cells this random segregation can result in rapid
loss of mutant mtDNA, as has been observed in blood
samples (Rahman et al., 2001). Furthermore, evidence
from multiple studies suggests that a bottleneck during
development results in rapid segregation of heteroplasmic
mtDNA, providing another route to homoplasmy (Upholt
and Dawid, 1977; Olivo et al., 1983; Holt et al., 1989; Vilkki
et al., 1990; Blok et al., 1997; Cree et al., 2008b). However,
the developmental phase at which the bottleneck occurs is
not clearly defined and is debated.
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A mosaic pattern of mtDNA is observed in COXdeficient muscle fibers of patients with mitochondrial
dysfunction. The suggested mechanism responsible for
this is called clonal expansion, and it is due to random
replication of mtDNA resulting in cells with differing
proportions of mutant to wild-type mtDNA. This will
result in loss of mutant mtDNA in some cells, providing
protection for those specific cells. However, the cells
that accumulate mutant mtDNA will over time develop
biochemical defects. Clonal expansion also happens in
postmitotic cells, explaining the accumulation of mutant
mtDNA with aging in muscle cells and neurons (Greaves et
al., 2012). The rapidly aging world population has generated
great interest in the involvement of mitochondria in aging,
and the mechanisms connecting mtDNA mechanisms
to aging are central to understanding the exact roles of
mitochondria in healthy aging.
2.4. Maternal inheritance
Unlike nDNA, mtDNA is transmitted to offspring
uniparentally, in most animals from the mother (Giles et

al., 1980). Maternal inheritance is widely accepted among
researchers; however, some published data suggest that
a limited degree of paternal inheritance can occur. For
example, some studies have suggested paternal inheritance
of a ND2 gene mutation (Schwartz and Vissing, 2002). The
existence of a low level of paternal inheritance has been
supported by subsequent studies and might account for
some rare familial mtDNA diseases with no identified
cause (Danan et al., 1999; Marchington et al., 2002; Filosto
et al., 2003; Taylor et al., 2003b; Schwartz and Vissing,
2004). However, maternal inheritance is far more likely
and should be examined as the more likely option to track
the familial history of the mutation.
3. Types and mechanisms of mtDNA dysfunction
3.1. Primary mutations
MtDNA point mutations and deletions can be classified
as primary mtDNA disorders (Figure 1). MtDNA point
mutations can occur in mt-tRNA, mt-rRNA, or mtmRNA. The clinical symptoms of mtDNA point mutations

Figure 1. nDNA and mtDNA mutations associated with mtDNA-related diseases. Mitochondria are surrounded by two membranes,
as shown in the upper left image. MtDNA is located within the matrix. A continuously cross-talk between mitochondria and nuclei
(upper right panel) is required for mitochondrial function. Mutations both in mtDNA and nDNA can result in mtDNA-related diseases.
Schematic representations of types of nDNA and mtDNA mutations that result in mtDNA-related diseases are listed in the lower panels.
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are heterogeneous, and in some cases the same mutation
can result in different symptoms. Most point mutations
that result in a clinical phenotype occur in mt-tRNA and
usually result in an overall reduction in mitochondrial
protein synthesis (Mariotti et al., 1994). In contrast, mtmRNA mutations usually (but not always) result in specific
respiratory complex defects (Figure 2). The diseasecausing heteroplasmy threshold can differ depending
on the type of mutation, with mtDNA deletions usually
having lower disease-causing threshold than mt-tRNA
mutations (approximately 60% vs. 80%; Kirino et al., 2004;
Taylor and Turnbull, 2005).
3.2. Point mutations
In general, point mutations are heteroplasmic and highly
recessive. However, there are reports of homoplasmic
mtDNA point mutations affecting a single tissue and
characterized by incomplete penetrance (McFarland
et al., 2002; Taylor et al., 2003a; Temperley et al., 2003;
McFarland et al., 2004; McFarland et al., 2007; Yang et al.,

2009). The three most common homoplasmic mutations,
causing Leber’s hereditary optic neuropathy (LHON),
are m.11778G > A, m.3460G > A, and m.14484T > C
(McFarland et al., 2007).
Here we focus on the three most common heteroplasmic
mutations observed in patients. The commonest mttRNA mutation is the m.3243A > G mutation on mttRNALeu(UUR), first characterized in a subgroup of patients
with mitochondrial encephalomyopathy, lactic acidosis,
and stroke-like episodes (MELAS) (Goto et al., 1990). More
recent studies reported that this mutation mostly results in
maternally inherited diabetes and deafness (MIDD) (Nesbitt
et al., 2013). The same study showed that this mutation can
result in progressive external ophthalmoplegia (PEO) and
that some affected individuals have overlapping symptoms
(i.e. MELAS + MIDD, MELAS + PEO, MIDD + PEO).
Furthermore, 9% of carriers show no clinical phenotype,
and the high levels of heterogeneity makes diagnosis of the
disease very challenging (Nesbitt et al., 2013).

Figure 2. Mechanisms of nDNA and mtDNA mutations associated with mtDNA-related diseases: mutations resulting in mtDNArelated diseases can either occur on mtDNA or nuclear genome (left, blue panel). These mutations have multiple targets, which can affect
various processes (middle, green panel). These can result in a single-complex or multiple-complex defect or mtDNA loss or a shift in
heteroplasmy; in all cases, OXPHOS activity is disrupted (right, red panel).
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The second most common heteroplasmic point
mutation is also on a tRNA gene. The m.8444A > G
substitution in mt-tRNALys (Shoffner et al., 1990) mostly
results in myoclonic epilepsy with ragged red fibers
(MERFF) and is also linked to some cases of a MIDD-like
syndrome (Santorelli et al., 1996a). Comparison of the
m.32343A > G and m.8444A > G mutations highlights the
clinical heterogeneity of mtDNA-related diseases, although
both cause OXPHOS defects through a decreased protein
synthesis rate (Yasukawa et al., 2000).
Clinically heterogeneous disease states also result from
an amino acid substitution (Leu 156 Arg) in ATP synthase
subunit 6, caused by the m.8993T > G mutation (Santorelli
et al., 1996b). This mutation is mainly linked to two
diseases: NARP (neuropathy, ataxia, retinitis pigmentosa)
and MILS (maternally inherited Leigh’s syndrome).
Interestingly, the mutation causes NARP at 90%–95%
heteroplasmy and causes MILS at higher heteroplasmy
rates (Tatuch et al., 1992).
3.3. Deletions
MtDNA deletions result from defects in mtDNA
replication, maintenance, and repair (Kaukonen, 2000;
Spelbrink et al., 2001). MtDNA deletions mostly occur
between origins of replication (OH and OL) and regions
flanked by tandem repeat sequences (Schon et al., 1989;
Krishnan et al., 2008). Deletions are normally sporadic,
occur in the germline, and are not transmitted to offspring
(Chinnery et al., 2004). The size of large-scale mtDNA
deletions varies, but many patients have a ~5-kb ‘commondeletion’ that spans the ATPase8 and ND5 genes as
represented in Figure 1 (Larsson and Holme, 1992).
The main determinants of clinical severity of a deletion
seem to be its abundance and tissue distribution, rather
than the size and location of the deletion itself (Tuppen
et al., 2010). However, recent studies also suggest a
correlation among deletion size, heteroplasmy, and clinical
severity (Grady et al., 2014).
MtDNA deletions are frequently associated with three
syndromes: Pearson syndrome, Kearns–Sayre syndrome
(KSS), and chronic progressive external ophthalmoplegia
(cPEO) (Zeviani et al., 1988; Moraes et al., 1989; Rotig
et al., 1990). Moreover, many studies have shown that
mtDNA deletions accumulate with aging and are mainly
linked to nervous system disorders (Cortopassi et al., 1992;
Bender et al., 2006; Kraytsberg et al., 2006). Increased
levels of mtDNA deletions have been found in the brains of
elderly individuals and in heart tissue affected by coronary
atherosclerosis (Corral-Debrinski et al., 1992a, 1992b).
3.4. mtDNA copy number maintenance
In addition to direct mutations in mtDNA, mtDNA
dysfunction can also be caused by mutations in nDNA
(Figure 1). MtDNA-related nuclear genes that cause
disease mainly affect mtDNA replication and copy number
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maintenance, and they fall into two categories: those that
directly affect the mtDNA replication fork and mutations
in genes that are involved in the supply of nucleotides for
mtDNA replication (such as mitochondrial thymidine
kinase TK2, the deoxyguanosine kinase dGK, and adenine
nucleotide transporter ANT1) (Copeland, 2008). The
effects of these mutations are sometimes called secondary
mtDNA defects. mtDNA copy number is regulated in
accordance with the energy demand of the cell. Cells under
a high energy demand, like muscle cells and neurons, thus
need to maintain high numbers of healthy and functional
mtDNA. This homeostasis can be disrupted either by
increased replication of mtDNA or by targeted degradation
of damaged mtDNA molecules (Szklarczyk et al., 2014).
There is some supporting evidence that oxidative stress
can increase mtDNA degradation (Shokolenko et al., 2009;
Furda et al., 2012).
Copy number maintenance is central to healthy
aging. mtDNA copy number decreases with aging in
different tissues, including pancreatic islets, skeletal
muscle, cerebral cortex, and heart muscle (Frahm et
al., 2005; Short et al., 2005; Cree et al., 2008a). Similar
observations have been reported in model organisms,
such as an age-related decrease in mtDNA copy number in
the rat CNS (McInerny et al., 2009). However, the impact
of mitochondrial dysfunction on aging varies between
species such as mice and humans (Greaves et al., 2011).
One study of two well-known mtDNA-related diseases,
MELAS and MERRF, showed an aging-related reduction in
mtDNA levels in leukocytes (Liu et al., 2006). Mutations in
the OPA1 gene, whose function is to induce mitochondrial
fragmentation, result in dominant optic atrophy (Alavi and
Fuhrmann, 2013). There are conflicting results concerning
whether this mutation results in mtDNA loss or mtDNA
proliferation (Iommarini et al., 2012; Sitarz et al., 2012).
Further work is needed to determine the mechanisms
of mtDNA replication and their involvement in disease
progression.
The factors needed for mtDNA replication are
completely encoded by nDNA. This adds another level
of complexity to the maintenance of a healthy mtDNA
population. MtDNA polymerase γ (Pol γ), a heterodimeric
protein consisting of a catalytic subunit (PolgA) and a
processivity subunit (polgB), is the exclusive mediator
of mtDNA polymerase activity (Carrodeguas et al.,
2001). Mitochondrial DNA helicase, also called Twinkle,
is responsible for 5’-3’ mtDNA helicase activity, and
mitochondrial single-strand binding protein (mtSSB) is
responsible for the stabilization of the single strand once
the double strand is unwound (Spelbrink et al., 2001).
Together with TFAM these proteins form the mitochondrial
replisome, which can be reconstituted in vitro (Korhonen
et al., 2004). The mechanism of mtDNA replication is
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not fully defined. There are mainly two models: strand
displacement and strand coupling (Clayton, 1982; Holt et
al., 2000). Both models have been critically appraised, but
a detailed description of this area is beyond the scope of
this review (Bogenhagen and Clayton, 2003b, 2003a; Holt
and Jacobs, 2003). Pol γ is one of the most widely studied
nuclear genes involved in mtDNA disorders because of
its high error rate of 1:50,000 bp (Longley et al., 2001).
More than 150 mutations in Pol γ have been identified in
patients with mtDNA disorders (Human DNA Pol Gamma
Mutation Database, http://tools.niehs.nih.gov/polg/).
These mutations can be found in all domains of Pol γ and
can cause PEO, Alpers syndrome (Naviaux and Nguyen,
2004), ataxia neuropathy (Van Goethem et al., 2004), and
male infertility (Rovio et al., 2001). A detailed overview of
Pol γ is available in the Human DNA Pol Gamma Mutation
Database (http://tools.niehs.nih.gov/polg/).
3.5. mtDNA depletion syndrome
Loss of mtDNA in tissues is usually identified as mtDNA
depletion syndrome (MDS). General clinical symptoms
include muscle weakness, progressive encephalopathy,
liver failure, and disturbed function of the skeletal muscle,
kidneys, and brain (Rahman and Poulton, 2009). MDS
was first characterized as an autosomal recessive disorder
(Moraes et al., 1991) and is widely reported in childhood
respiratory deficiency syndromes (Sarzi et al., 2007).
The genetic alterations leading to MDS commonly
affect the mtDNA replication components (Pol γ, Twinkle,
TFAM) (Spelbrink et al., 2001), but they can also involve
genes required for the supply of sufficient dNTPs for
mtDNA replication. dNTPs are supplied to mitochondria
either by active transport of cytosolic dNTPs or through
a salvage pathway that mainly requires TK2 (thymidine
kinase 2) (Suomalainen and Isohanni, 2010). Mutations
in TK2 have been reported as the most common cause of
MDS (Saada et al., 2001). MDS can also be triggered by
mutations in dGK (Mandel et al., 2001) or ribonucleotide
reductase (Bornstein et al., 2008), and another
enzyme important for maintaining the dNTP pool, TP
(thymidine phosphorylase), causes the mtDNA-related
disease MNGIE (mitochondrial neurogastrointestinal
encephalomyopathy) (Nishino et al., 1999).
4. Clinical, biochemical features, and diagnosis of
mtDNA-related diseases
4.1. Clinical assessment and examination
The diagnosis of mtDNA-related diseases is quite complex,
which should be extensive. The age of onset of mtDNArelated diseases is variable and is determined primarily
by the severity of the defect and the mutation load and
to a lesser extent by environmental and nuclear genetic
modifier factors. It is common to classify mtDNA-related
diseases into two groups: ‘early infancy and childhood’ vs.

‘late childhood and adulthood’. Leigh syndrome, mtDNA
depletion syndromes, KSS, and Pearson syndrome fall
into the first group, while mitochondrial encephalopathy,
MELAS, cPEO, neuropathy, NARP, LHON, and
MERRF are usually observed in late childhood and
adulthood (Tuppen et al., 2010). The high degree of
tissue heterogeneity is another hallmark of mtDNArelated diseases. Neurological, gastrointestinal, cardiac,
respiratory, endocrinal, ophthalmological, hematological,
renal, muscular system, and liver failure are involved in
mtDNA-related diseases (Vafai and Mootha, 2012).
In order to assess the clinical situation of a patient, the
clinician should carry out various tests on the possible
organ systems that could be involved in the disease.
One group of these tests is based on imaging. Cardiac
failure can be investigated by electrocardiography
(ECG), electromyography (EMG) can reveal muscular
defects, and computed tomography (CT) and magnetic
resonance imaging (MRI) findings can help to evaluate
the patients’ condition (Menezes et al., 2014). Certain
blood-based biochemical tests have shown promise as
diagnostic tools for mitochondrial disorders. Measuring
the level of lactate, pyruvate, creatine kinase, total blood
count, thyroid and liver function, bone chemistry, and
blood glucose levels can be informative (Naviaux, 2004).
For example, it is common to observe high lactate and
pyruvate levels in patients with mitochondrial disorders as
a result of a compensatory mechanism to overcome ATP
deficit; however, this is not always observed in LHON and
KSS. Organic acids and amino acid profiles measured by
chromatography, mass spectrometry, or HPLC can aid
the observations. Although a clear correlation is missing,
an increase in alanine, proline, glycine, sarcosine, and
tyrosine can be observed in mtDNA-related diseases. In
addition, novel biomarker discoveries are expected to help
towards the diagnosis of mitochondrial disorders, thereby
decreasing the diagnostic work currently required. So far,
cytokine FGF-21 (fibroblast growth factor-21) has been
found to be a biomarker for muscle-specific mitochondrial
diseases (Suomalainen et al., 2011).
4.2. Histopathology
Regardless of the underlying mutation, all mtDNA-related
disorders result in defects in oxidative phosphorylation
as shown in Figure 2 (Betts et al., 2004). However, tissue
heterogeneity and specificity remain the major reasons for
the need of detailed analysis of mitochondrial function
in different tissues, if possible. In order to carry out a
more extensive assessment, a muscle biopsy is needed
since this tissue mostly, but not always, shows a defect
in most of the mtDNA-related diseases (Janssen et al.,
2003). Effective communication with the patient is needed
at this stage in order to obtain a muscle biopsy sample
together with a fibroblast sample, both of which can be
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used for subsequent analysis. One of the most established
techniques is the staining of the muscle fibers with Gomori
trichrome, which results in ragged red fibers (RRFs),
which reflect the abnormal subsarcolemmal accumulation
of mitochondria (Tuppen et al., 2010). The most common
and penetrant phenotype is COX (cytochrome c oxidase)
deficiency, first reported in chronic PEO patients’
fibers (Johnson et al., 1983). COX/SDH (succinate
dehydrogenase) immunohistochemical double-staining
is commonly used to classify normal versus deficient cells
in mitochondrial diseases. SDH staining shows a normal
pattern in disorders caused only by mtDNA defects but
not by nDNA (so-called primary mtDNA mutations),
since all subunits of complex II are encoded by nDNA.
Therefore, SDH staining can be mainly used to identify
complex II defects. COX staining can result in a mosaic
pattern, or in some cases, global and uniform decrease is
observed. Mosaic COX deficiency highlights heteroplasmy
differences; on the other hand, uniform COX defects
are related to nDNA mutations mainly encoding COX
subunits and assembly factors (e.g., SURF1, SCO2) (Zhu et
al., 1998). It should also be noted that COX deficiency may
be observed upon aging since there is an accumulation of
mtDNA mutations by age (Brierley et al., 1998). Such cases
should be classified in the context of aging rather than
specific mtDNA-related diseases. Finally, more analysis
can be made by measuring mitochondrial ultrastructure
using electron microscopy and respiratory chain complex
activities from isolated mitochondria; however, these also
depend on the availability of the materials and resources.
A more detailed explanation of clinical symptoms and
histopathological findings was reviewed elsewhere (Taylor
and Turnbull, 2005; Greaves et al., 2012).
4.3. DNA-based diagnosis
The detailed investigation of the family history of the
patient may reveal the genetic defect of the individual
and help to differentiate whether it is mtDNA or nDNA
related, since mtDNA has a maternal inheritance. In detail,
observation of mtDNA deletions usually reflects a defect in
mtDNA maintenance genes (e.g., PolG, PEO1, OPA1) and
mtDNA depletion reflects defective mtDNA replication
related to the replication genes (PolG, mtSSBP, Twinkle,
Tfam) or genes involved in the supply of the dNTP pool
(TK2, dGK). In some cases, the clinical phenotypes may
reflect a common mutation causing well-defined diseases
such as MELAS (m.3243A>G) or MERRF (m.8344A>G).
In such cases, a direct sequencing of the genetic location
or RFLP can be applied. Additionally, the heteroplasmy
levels of these mutations should be determined either by
RFLP or TaqMan real-time PCR analysis. Furthermore,
long-range PCR or real-time PCR can be used to detect
the mtDNA deletions (He et al., 2002). These primary
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mtDNA defects were discussed in the earlier sections of
this study. Furthermore, mtDNA depletion, caused by
nDNA-encoded gene mutations (for details, see Section
3), can be detected by real-time PCR. There are many
cases where the disease-causing mutation on mtDNA has
not been defined before. Direct sequencing of the whole
mtDNA can provide much information. However, care
should be taken while choosing the candidate mutation
and a pathogenic disease causing mutation. The criteria for
this were published by DiMauro and Schon and we refer
their work for this purpose (DiMauro and Schon, 2001).
The improvements in sequencing technologies
allowed the usage of next-generation sequencing (NGS)
as a new way to diagnose mitochondrial diseases. Recent
figures show that NGS allowed not only to assign already
characterized mutations to patients but also to discover
novel mutations (Menezes et al., 2014). Whole-genome
sequencing (WGS) is still very expensive to be used on a
daily basis, but whole-exome sequencing (WES) has been
used commonly in recent years. Although intronic defects
can be linked to some diseases, most genetic diseases are
caused by mutations present in exons (coding regions),
which correspond to less than 2% of the whole genome. By
using WES, all of the variants in exons can be detected in a
single experiment rather than in several sequencing runs.
The difficulty in this is to assign a variant as a diseasecausing variant. Here, we refer to a recent review published
by Suomalainen’s group for details and criteria of variant
identification (Carroll et al., 2014). A more targeted
approach for mitochondrial diseases can be taken by using
MitoExome, which has been proven to detect both known
and novel mutations causing mitochondrial diseases.
Independent studies have shown that this methodology
can be applied successfully (Calvo et al., 2012; Vasta et al.,
2012; Lieber et al., 2013). All these advances in sequencing
resulted in characterizing around 50 novel mutations,
although recent reports highlight that more improvements
are needed. Two independent studies carried out at
hospitals in Japan and the United States show that for
around 50% of the WES cases, the functional pathogenic
(disease-causing) variant could not be determined (Lieber
et al., 2013; Ohtake et al., 2014). Better comparative analyses
will be made possible by including more sequencing data
of more cases (especially control for nonmitochondrial
diseases). More reliable sequencing reactions are also
needed together with efficient bioinformatics tools. In any
case, assigning a highly probable variant (mutation) as a
disease-causing variant remains a challenge. Therefore,
functional studies on cells (depending on the availability)
should be performed before making a decision about a
causative DNA variant (Danhauser et al., 2011).
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5. Potential treatment strategies
5.1. Treatments to improve quality of life
Improving the quality of life of the patients should be the
primary goal to be achieved right after the diagnosis. It has
been shown that exercise therapy can help this; however,
it neither stops nor prevents the occurrence of the disease.
Aerobic training proved to improve OXPHOS activity and
exercise capacity of patients with mitochondrial myopathy
(Jeppesen et al., 2006). Furthermore, endurance exercise
improved mitochondrial myopathy symptoms in a mouse
model of the disease (Wenz et al., 2009).
Controlled and optimized diet can also help to improve
quality of life. A ketogenic diet, rich in fat and low in
glucose, results in high amounts of mitochondrial betaoxidation and ketone body production, which has been
shown to slow the progression of mitochondrial myopathy
in mice (Ahola-Erkkila et al., 2010). Other multiple studies
have shown various phenotypically beneficial effects such
as reduction in epileptic seizures, improved brain energy
metabolism, inhibition of ROS production, and increased
neuroglia interaction and ATP concentrations (Khan et
al., 2015). Furthermore, a ketogenic diet was found to
decrease the level of deleted mtDNA copies, causing a shift
in heteroplasmy, in cultured human cells (Santra et al.,
2004).
Most treatment strategies for mtDNA-related diseases
follow the guidelines published by the Wellcome Trust
Centre for Mitochondrial Research in Newcastle, UK
(http://www.newcastle-mitochondria.com/service/
patient-care-guidelines/). The discovery of mtDNA
mutations and progress in our understanding of disease
mechanisms have paved the way toward potential cures
for mtDNA-related diseases. Experimental animal models
have been very informative in defining and tailoring
treatment strategies. Animal models of mtDNA-related
disorders are described in a number of valuable and
detailed reviews (Oliveira et al., 2010; Palladino, 2010;
Dogan and Trifunovic, 2011; Dunn et al., 2012).
5.2. Pharmacological treatments
Potential therapeutic strategies are focused on the
positive effects of pharmacological and biochemical
agents observed in cellular and animal models. One of
the frequently observed outcomes of mtDNA-related
disorders is a change (usually an increase) in the level of
oxidative stress. Mitochondria are a major producer of
cellular ROS and multiple mtDNA mutations have been
shown to result in increased ROS. The neurodegeneration
phenotype observed in LHON patients was found to be
caused by increased level of ROS. Creation of cybrid lines
harboring 11,778 and 3460 mutations and subsequently
differentiating them into neurons resulted in increased
ROS (more in 3460 mutations); however, undifferentiated
cells did not show any difference (Wong et al., 2002).

Two NARP-causing mutations at the same location
(m8993T>G and m8993T>C) are reported to cause
increased ROS production and SOD activity (Baracca et
al., 2007). It is worth further emphasizing that although
these two mutations occur at the same location, the level
of increase in ROS is different. Furthermore, increased
ROS production was observed in different tissues (heart
and brain) in a heteroplasmic mouse model harboring
the commonly observed m3243A>G tRNA mutation (Li
et al., 2008). In view of the focus of this special issue on
‘Melatonin and Mitochondria Interact in Diseases’, we
detail here some of the recent advances on the potentially
beneficial effects of melatonin, and specifically mtDNArelated disorders.
The hormone melatonin, secreted by the pineal gland,
is a potent free-radical scavenger and regulates redoxactive enzymes (Galano et al., 2011). Melatonin is also
regarded as a possible mitochondrial protector and can
restore mitochondrial function in a mouse model of
Alzheimer disease involving a transgenic mutant form of
APP (amyloid precursor protein) (Dragicevic et al., 2011).
More information related to the roles of melatonin in
neurodegenerative process can be found in the literature
(Pandi-Perumal et al., 2013). A recent study was carried
out on NARP cybrids harboring 98% heteroplasmy in the
m.8993T > G mutation, which is associated with a defect
in F1F0-ATP synthase. Melatonin has been reported to
have the potential to rescue heart function in patients after
myocardial ischemia/reperfusion (Huang et al., 2013), a
conclusion supported by similar studies (Peng et al., 2012).
As explained earlier, the ~5-kb ‘common-deletion’ is
widely observed in patients with mtDNA-related diseases.
The increased mitochondrial ROS (mROS) production
associated with the common deletion can be rescued by
melatonin, preventing mROS-mediated depolarization of
membrane potential (Jou et al., 2007).
Furthermore, the lifespan-extending effect of
rapamycin (Bonawitz et al., 2007; Pan et al., 2012) has
been shown to have a mtDNA origin (Villa-Cuesta et al.,
2014). This further highlights the complex dual control of
mitochondrial homeostasis. Potential dietary therapeutic
approaches have also explored the potential of alphaketoglutarate/aspartate supplements (Sgarbi et al., 2009).
Continuing research in this area will provide additional or
complementary therapeutic opportunities.
Similar approaches have been used to study the potential
benefits other metabolites and vitamins, etc. Frequently
cocktails of various cofactors and vitamins are being used.
The choice of these agents is usually made if the molecule
under question is defective, less produced, or mutated or if
its transport is being impaired. Here we summarize most
of the molecules used for the treatment of mitochondrial
diseases. Coenzyme Q10 (CoQ10, ubiquinone) is part
of the electron transport chain and it is also a ROS
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scavenger (Ernster and Dallner, 1995). CoQ10 deficiency
is commonly observed in various different mitochondrial
diseases and CoQ10 supplementation has been overall
successful (Quinzii and Hirano, 2010). Riboflavin (watersoluble vitamin B, B2) is a precursor of flavoprotein, which
has key roles for complex I, complex II, the Krebs cycle,
and fatty acid oxidation. Therefore, riboflavin is usually
supplied in complex I and complex II diseases (Bernsen
et al., 1993; Bugiani et al., 2006). Creatine is found at
high concentrations in energy-demanding tissues such
as the muscle and brain. It can be classified as an energyboosting compound since it forms phosphocreatine,
which is a source of high-energy phosphate. It has been
used in combination with CoQ10 (Dimauro and Rustin,
2009). L-Arginine, which is a semiessential amino acid,
has been successfully used for treatment of MELAS (Koga
et al., 2002). Carnitine, which has a key role in fatty acid
metabolism, is used to increase free carnitine levels and is
usually used together with CoQ10 (Marriage et al., 2004).
Dichloroacetate (DCA) is a lactic acid-lowering molecule
that can be targeted to patients with increased lactate or
lactic acidosis. However, a double-blinded MELAS study
showed toxic effects of DCA, which resulted in decline of
its use (Kaufmann et al., 2006). Idebenone is an analogue
of CoQ and has been used in LHON patients with some
degree of success (Carelli et al., 2011). Vitamins B1, C, and
E and alpha-lipoic acid, dimethylglycine, and whey-based
glycine are other molecules in use. For a detailed review
of each of these molecules we refer to the very valuable
work of others (Parikh et al., 2009; Kanabus et al., 2014).
Compounds undergoing clinical trials between 1997 and
2012 were also recently reviewed (Kerr, 2013).
There are other pharmacological agents present on the
verge of clinical trials for the treatment of mitochondrial
diseases. One group of such agents with promising
outcomes are focused on increasing mitochondrial
biogenesis via PGC1α, PPARs, NRF1/2, YY1, and ERRs
(Andreux et al., 2013) . Bezafibrate, which is a synthetic
ligand of PPARα, has been proposed to be a new
pharmacological agent supported by several positive results
obtained in mouse models (Kanabus et al., 2014). A clinical
trial of bezafibrate in mitochondrial disorders is missing,
although promising observations were made in a clinical
trial of a fatty acid oxidation disorder called carnitine
palmitoyl transferase 2 (CPT2) deficiency (Bonnefont
et al., 2010). Another candidate targeting mitochondrial
biogenesis is resveratrol, which is an activator of sirtuin
SIRT1. Until now, resveratrol has only been included
in a clinical trial of healthy elderly individuals (rather
than mitochondrial disease patients), and increased
mitochondrial function was observed (Libri et al., 2012).
Finally, AICAR, which is an AMPK activator, was tested
in human complex I-deficient fibroblasts and promising
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results were obtained, such as increased ATP levels and
decreased ROS (Golubitzky et al., 2011). In summary, very
detailed clinical trials are needed in order to determine the
benefits of using mitochondrial biogenesis activators as
new therapeutic agents.
In addition to ROS, other toxic substances such
as hydrogen sulfide (H2S) are also the target of some
potential treatments. It has been shown that NAC and
metronidazole treatment is useful for ethylmalonic
encephalopathy (Viscomi et al., 2010). Furthermore,
targeting mitochondrial dynamics, autophagy, and
mitochondrial membrane lipids are other possibilities that
need to be investigated at the preclinical level (Andreux et
al., 2013).
5.3. Gene therapy
Current treatment strategies are aimed at ameliorating
symptoms and reducing the risk of complications. Cure
and prevention of mtDNA-related diseases, however,
requires more effective treatments. The primary goal for an
effective gene therapy of mtDNA-related diseases is to alter
the level of heteroplasmy, either by targeted degradation of
mutant mtDNA or by blocking replication (Taylor et al.,
1997).
The earliest gene therapy trials, started in the late
1990s, tested the potential of mitochondria-targeted
peptide nucleic acid (PNA) oligomers, which are DNAlike molecules with an aminoglycine backbone instead of
phosphate ribose groups. In vitro assays showed that this
technique could prevent replication of mutant mtDNA
copies; however, cell line studies were less successful
(Chinnery et al., 1999).
The next approach tried was to target mitochondrial
genes with endonucleases. The m.8993T > G mutation
is known to generate a specific SmaI endonuclease
cleavage site. Therefore, delivery of SmaI to mitochondria
containing the mutant mtDNA has the potential to deplete
mutant mtDNA copies and result in biochemical rescue
(Tanaka et al., 2002). Further advances in this field have
been made possible by the use of chimeric zinc finger
methylases (Minczuk et al., 2006). Use of specific zinc
finger peptides (ZFPs) to target the m.8993T > G mutation
resulted in reduction of heteroplasmy over a 30-day period
(Minczuk et al., 2008). More recently, the development of
transcription activator-like effectors (TALEs) and TALE
nucleases (TALENs) has produced very promising results
for mtDNA gene therapy (Boch et al., 2009; Hockemeyer
et al., 2011). The use of TALENs resulted in reductions in
heteroplasmy from 70% to 30% without affecting mtDNA
copy number (Bacman et al., 2012). Supporting results have
also been reported in a cybrid cell model of the common
deletion (Gammage et al., 2014). Detailed analysis of these
improvements are needed, and these techniques and their
potential uses were critically evaluated in recent reviews
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(Kaufmann et al., 2013; Moraes et al., 2014). Furthermore,
it has been reported recently that the transmission of
mtDNA mutations can be prevented in the germline by
the use of TALENs to eliminate mutated mtDNA copies
(Reddy et al., 2015). The same group also adapted the
‘MitoTALENs’ technology, so they can be used by viral
delivery vectors (Hashimoto et al., 2015). The common
expectation in the field is to start testing this technology
on patients who are waiting to be treated.
5.4. Genetic counseling
One of the most ideal strategies is to prevent mtDNArelated disease before it occurs. Therefore, genetic
counseling and prenatal diagnosis have started to be
applied. Informing parents about the real risk of having
a child with a mitochondrial disease should be done by
professionals.
Mechanism of transmission and segregation of mtDNA
species (mutated and nonmutated) in the germline is not
fully understood; therefore, prenatal genetic diagnosis
resulted in limited success (Poulton et al., 2009).
Although it is not possible to estimate heteroplasmy
levels in individual tissues, and therefore not possible
to predict clinical outcomes, prenatal genetic diagnosis
has reportedly been applied successfully in several cases
(Bouchet et al., 2006). Due to these uncertainties, parents
are aiming to have offspring without any mutated mtDNA
copies by the help of preimplantation genetic diagnosis
(PGD) (Hellebrekers et al., 2012).
6. Concluding remarks
Mitochondria are central to many processes in the cell,
and disturbances to ATP metabolism trigger a wide range
of symptoms. Increasing evidence has implicated mtDNA

defects in numerous diseases such as LHON, MELAS,
PEO, NARP, MILS, KSS, and Pearson syndrome and also
in broader diseases such as neurodegeneration and cancer.
A healthy mtDNA population is vital for the maintenance
of efficient ATP production. However, further detailed
research into the mechanisms of mtDNA-related diseases
is required to develop effective diagnostic and treatment
options. Recent advances in NGS discussed here will be
particularly useful for effective diagnosis of patients.
More detailed clinical trials incorporating mtDNA-related
targets promise optimized pharmacological treatments in
the coming years. Recent improvements in gene therapy are
very promising, especially the use of TALENs, which has
been successfully reported for the treatment of LHON and
NARP. The first clinical trials of gene therapy are expected
to start in the next few years. Global, multidisciplinary,
and collaborative work on mtDNA-related diseases will be
fundamental for the discovery of effective diagnostic and
therapeutic strategies.
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